Reginald Seeto: Sure. So there are two pieces of your question, Andrew, the first 1 around the collection improvements and how that is going to help us bridge the gap between the headwind that we see on the payer mix and of course, the benefit of the volume. So the way I’ve guided this time, so our ASP was mid-teens decline last year. But this time, we are assuming low double digit or probably at somewhere around 10% decline. So the 5% is what I’m assuming based on the improved collection efforts, right? And that is basically what I’m baking in throughout the year as we move along. As our collections of 110% that we have seen in the quarter — last quarter, if we continue to collect more, then, of course, this is going to help us going forward as a positive.
On your second part of the question around the R&D. So the R&D expenses, there were a couple of things going on this quarter. The first one was the milestone payment. So of course, we had these agreements with some of the partners in the past where we basically pay them while achieving certain milestones. And one of those contracts basically required us to pay for the milestone, and that’s where that payment came in, that was a onetime one. And the second one, of course, is — the clinical study payments, as you would know that the startup cost would always stay a little bit more bumpy. And we paid some start-up costs in Q4 that basically increase the R&D plan. One thing quickly, — and just to lay out the expectations well some of the for this year, at least, that metric of looking at collections versus testing service revenue line that we anticipate to keep on sharing in a positive way as well.
So I think that should be just to set the cadence as well. But thank you again for the questions.
Andrew Cooper: Thanks. I’ll jump back in the queue.
Operator: Our next question is from Matt Sykes with Goldman Sachs. Please proceed.
Matthew Sykes: Hi, good afternoon. Thanks for taking my questions. Maybe my first one, you had mentioned Reg, that post the ISHLT guidelines that you had had some conversations further conversations with payers. We’d love to know kind of what the feedback is from those conversations in terms of are these guys that they’re waiting for? And do you think you can achieve some momentum from that that you’re obviously not baking to your guide that we could see in 2023 from a coverage standpoint?
Reginald Seeto: Yes. I see Matt. We were thrilled to get the ISHLT guidelines and what was shared at the end of last year is one of the areas we thought would be important for the organization, particularly as we look at LP coverage. I think I’d break it out to twofold. The first is on AlloMap, I think firstly, AlloMap is our FDA cleared test gene expression profiling, sort of published in New England. And what was clear to us in the guidelines is there should be earlier coverage starting at month two. And there are some commercial payers today that don’t cover us that early. And so this has led us to actually initiate several discussions already with some national and regional payers already this quarter to start those discussions.
So there has been, firstly, receptivity to have those discussions, secondly, to allow us to present the information and then allow us to present some further rationale behind that earlier start, particularly because it’s given in the guidelines and names specifically. So I think it’s an on-going process, but one we’re particularly pleased with. The second is, if you look at HeartCare itself, this is an area which has now allowed us to actually trigger some of those discussions. As a reminder, previously, we weren’t necessarily getting those discussions on an ad hoc basis or even a routine basis with with AlloSure part. But now there’s guidelines coming through, particularly with the recommended testing and also looking at some of the settings such as during COVID has now allowed us to initiate those ad hoc discussions that is off cycle and allow those to take place as well.
